Results 141 to 150 of about 1,948,666 (273)
ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe +13 more
wiley +1 more source
Ring-opened analogues of dihydrobenzopyran potassium channel openers (PCOs) were prepared and evaluated as putative PCOs on rat aorta rings (myorelaxant effect) and rat pancreatic beta-cells (inhibition of insulin secretion).
Lebrun, P. +23 more
core +1 more source
Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi +7 more
wiley +1 more source
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran +3 more
wiley +1 more source
ABSTRACT Aims Metformin, the first‐line treatment for Type 2 diabetes mellitus (T2DM), may be neuroprotective but also lowers serum vitamin B12 by ~19%, raising concern that B12 depletion could offset this benefit. We used modern exploratory causal mediation methods in a nationally representative sample to test whether vitamin B12 and methylmalonic ...
Danial Fotros +2 more
wiley +1 more source
Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke
In MEPS 2017'2023, 2,241 person‐years represented approximately 3.05 million U.S. adults with diabetes and a history of stroke annually. Survey‐weighted use of GLP‐1RAs or SGLT2 inhibitors increased from 8.7% to 33.8% (OR per year, 1.36; P < 0.001). Stroke‐history associations with insulin and metformin use attenuated after clinical adjustment and did ...
Yaojie Cai, Yu‐Jun Xiong, Tian Lv
wiley +1 more source
Genetic variation influences the pharmacological response to metformin and SGLT2 inhibitors in patients with type 2 diabetes mellitus. Pharmacogenetic biomarkers affecting drug transport, metabolism and target activity contribute to inter‐individual differences in treatment efficacy and adverse effects, supporting the implementation of personalized ...
Imran Hossain +6 more
wiley +1 more source
ABSTRACT Background and Aims The prevalence of diabetes mellitus is on the rise globally, presenting a significant challenge to healthcare systems, particularly in developing countries like Bangladesh. However, treatment modalities, care‐seeking attitudes and clinical profiles among these patients are not well explored. This descriptive cross‐sectional
Md. Shamsur Rahman Sweet +4 more
wiley +1 more source
This study investigated the utility of capillary electrochromatography columns based on magnetic particles with immobilized serum albumin for studying the binding of drugs to plasma proteins. To the best of the authors’ knowledge, this is the first report describing an affinity interaction between drugs and bovine serum albumin using this type of ...
Michal Sedlák +3 more
wiley +1 more source
ABSTRACT Objective This study aimed to evaluate the effects of laser photobiomodulation (PBM) using the systemic vascular technique (VPBM) on glycemic control in individuals with type 2 diabetes mellitus (T2DM) undergoing conventional pharmacological treatment.
Leandro Augusto Almeida +4 more
wiley +1 more source

